Past studies indicate CML leukaemic stem cell (LSC) survival is BCR::ABL1 kinase-independent [7], and persistence of TKI-insensitive LSCs is thought to underpin our inability to cure more patients [8]. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.